• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    16-Fluoro-16,17-didehydro prostanoids of formula: <IMAGE> wherein R is 1)-OH or -OR', wherein R' is C1-C6 alkyl optionally substituted by phenyl, monocycloalkyl or a heteromonocylic ring; <IMAGE> wherein each of R'' and R''' is, independently, hydrogen; C1-C6 alkyl; phenyl; or a heteromonocyclic ring; or R'' and R''', together with the nitrogen atom to which they are linked, form a heteromonocyclic ring -W-(CH2)n-X where W is -O- or -NH-, n is an integer of 1 to 4 and X represents a group -OR' or a group <IMAGE> or 4) -NHSO2-R<IV>, wherein R<IV> is C1-C4 alkyl, phenyl or phenyl substituted by C1-C4 alkyl; one of R1 and R2 is hydrogen and the other is hydroxy or R1 or R2, taken together, form an oxo group; one of R3 and R4 is hydrogen and the other is hydroxy or R3 and R4 are both hydrogen or, taken together, form an oxo group; one of R5 and R6 is hydroxy and the other is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl or phenyl; m is zero or an integer of 1 to 3; R7 is C1-C6 alkyl; C3-C7 monocycloalkyl; unsubstituted phenyl or phenyl substituted by one or more substituents chosen from C1-C4 alkyl; C1-C4 alkoxy, tri-halo-C1-C4-alkyl, halogen, <IMAGE> wherein each of R<V> and R<VI> is, independently, hydrogen, C1-C4 alkyl or phenyl; or R7 is a heteromonocyclic ring optionally substituted by one or more of halogen, C1-C4 alkyl, C1-C4 alkoxy, phenyl and phenoxy; A is trans -CH = CH-, -CH2-CH2- or -C IDENTICAL C-, and the symbol @ represents a single bond or a cis double bond; with the condition that R3 and R4 do not form an oxo group when R1 and R2 form an oxo group; and the pharmaceutically or veterinarily acceptable salts thereof; are useful as luteolytic, anti-ulcer and anti-neoplastic agents and can inhibit platelet aggregation.
    公开号:SU1442070A3
    申请号:SU853961258
    申请日:1985-10-10
    公开日:1988-11-30
    发明作者:Фаустини Франко；Дъалессио Роберто；Панцери Акилле；Ди Салле Энрико
    申请人:Фармиталиа Карло Эрба С.П.А. (Фирма)；
    IPC主号:
    专利说明:

    The invention relates to a process for the preparation of new 16-fluoro-16,17-dideo-hydroprostanoid, a total
    COR
    (I)
    they
    where R is the OH group or the OR group, where D is the lower C -C4-alksh1,
    one of R, and R, j g H, and the other is OH,
    one of RJ and R. N, and the other Ori, with valuable pharmacological properties.
    The purpose of the invention is to obtain new derivatives of fluorine containing prostanoids with valuable pharmacological properties.
    Example 1
    A. To a solution consisting of 0.530 g of methyl ester 5Z, 13E, 16Z-9 /, 11 of 15R-tripioxy-9-acetate-16-fluoro-18,19,20-trinor-17-phenyl-prosta- 5,13,16-trienoic acid in 10 ml of anhydrous CHgCl. 0.252 ml of dihydropyran and a catalytic amount of p-toluenesulfonic acid (approximately 0.003 g) are added. The resulting solution was stirred at room temperature for 2 hours, then extracted with diethyl yfir (50 ml), washed twice with 5% NaHCOa solution, then twice with water and dried. The solvent is removed in vacuo. The crude sheds (0.680 g) are dissolved in 10 ml of anhydrous methanol, and then 0.191 g of potassium carbonate is added. The resulting solution is stirred at room temperature for 6 hours and then treated with 30% aqueous NaHjPO solution (50 ml) and extracted with 4 portions of 30 ml each of ethyl acetate. The resulting organic phase is washed, dried and the solvent is distilled off under vacuum. The residue obtained is purified by flash chromatography on silica gel using a mixture consisting of ethyl acetate and n-hexane (40:60) as eluent.
    Get 0,496 g of pure methyl ether 5Z, 13E, 16Z-9d,
    0
    five
    0
    five
    0 5
    0
    five
    -trioxy-Ev, 19,20-trinor-16-fluoro-17-phenylprost-5,13,16-trienoic acid 1 1,15-bis-tetrahydropyran ester.
    B. A solution consisting of 0.86 g of methyl ester 5Z, 13E, 16Z-9df, 11 d-15R-tripioxy-9-acetate-16-fluoro-18.19, 20-trinor-17-phenylprosta-5, 13,16-trienoic acid-11,15-bis-tetrahydropyran ester in 15 ml of methanol, is reacted at room temperature for 3 hours with a solution of 0.3 g of lithium hydroxide in 3 MP of water. The mixture is treated with a 10% aqueous solution of 6.2, then the mixture is extracted with ethyl acetate, washed with water and dried with sodium sulfate.
    After removal of the solvent, 0.75 g of 5Z, 13E, 16Z-9o, 1Y-15R- -trioxy-16-fluorop18, 19,20-trinor-17-phenylproprosta-5,13,16-trieneic acid are obtained. - lots-11,15-bis-tetrahydropyran (THP) ether.
    I. Similarly, using the corresponding intermediates as starting compounds, the following 11,15-bis-THP ethers are obtained:
    Methyl ester 5Z, 13E, 16Z-9 / -t5S- -dioxy-9-acetate-16-fluoro-18,19,20-trinor-17-phenylprosta-5,13,16-trienoic acid, less polar Compound, CaCjj, +68, P, UJ34S +228.6 (, EtOH);
    Methyl ester 5Z, 13E, 16Z79 (/ - 13R-dioxy-9-acetate-16-fluoro-18,19,20- -trinor-17-phenylrost-5,13,1b-trienoic acid, more polar compound , + 21.8% WJ365 + 27 (, EtOH); NMR (CDCl) ,, namlch; 3.64 (38, s.); 4.79 (1H, d.); 5.37 (2H, m.); 5.82 (2H, M.) J 5.85- (IH, d.); 7.2-7.6 (5H, m.).
    PRI mme R 2. To a solution containing 0.450 g of methyl zfire 5Z, 13E 9of-15R-dioxy-9-acetate-18,19, 20-trinor-16-fluoro-17- (2-furyl) - simple-5,13,16-trienoic acid in 3 ml of dry, dimethylformamide, 0.070 g of imidazole and 0.147 g of tert-butyl dimethyl chlorosilane are added. The resulting solution is stirred for 6 hours at room temperature, and then the reaction is quickly stopped by the addition of 40 ml of ice-cold water. Solution. extracted three times with diethyl rum (30 ml). The resulting organic phase is washed with water, dried and the solvent is distilled off under reduced pressure. The resulting crude product is purified by flash chromatography on silica gel using a mixture consisting of ethyl acetate and hexahane in the ratio of 20:80 as eluent. The result is 0.506 g of pure methyl ester 5Z, 13E-9o-15R-dioxyl-18,19,20-trinop-16-fluorop-17- (2 -pyryl) -prost-5,13,16-triene 15-tert-butyl acid and methyl ester acids; Dissolve the resulting product (0.400 g) in 5 ml of anhydrous methanol and then 0.075 g of potassium carbonate is added. The resulting mixture was stirred for 8 hours, and then the reaction was quickly stopped by adding 40 ml of a 30% aqueous NaHRO solution. The mixture is extracted with ethyl acetate, dried and evaporated to dryness. The result is 0.452 g of methyl, yfira 5g, 13E-9 / -15K-daoxy-18,19-20-three nor-16-ft6p-17- (2-furyl) -prost-5i13,16-triene acids of 15-tert.-butyl dimethylsilyl ester. The resulting product is dissolved in 10 ml of bevodic benzene and in 1 ml of dimethyl sulfoxide (DMSO), and then 0.161 g of dicyclohexylcarbodiimide and 0.1 ml of a 0.1 M solution of pyridinium trifluoroacetate are added. The resulting solution is stirred for 1 h at room temperature and then 6 m of a 30% aqueous solution of NaHjPO are added - The solid material is filtered and washed with benzene, the organic phase is washed with water, dried and the solvent is removed. The result is a crude methyl ester of 9-oxo-5g, 13E-15K-hydroxy-18,19,20-trinor-16-fluoro-17- (2-furyl) -prost-5,13, 16-trienoic acid 15-tert-butyl-dimethylsilyl ether (0.450 g).
    I
    To a solution of the crude product in 15 ml
    tetrahydrofuran (THF) 0.220 g of acetic acid and 0.320 g of tetrabutylammonium fluoride are added. The mixture was stirred for 8 hours at room temperature. The reaction mixture is diluted with 50 ml of ethyl acetate, washed with 5% NaHCO, j and water, then dried and the solvent is removed. The crude product is purified by chromatography on silica gel using as eluent
    a mixture consisting of ethyl acetate and n-hexane in a ratio of 70:30.
    0.215 g of pure 5Z methyl ester is obtained, 13E-9-oco-15R-oxy- 1 8, 1 9, 20-trine OP-1 6-fluoro-1 7- (2 -fyl-propyl) -prostate 5, 13,16-trienoic acid, -27.4 (, EtOH).
    Similarly, from the derivatives of prostate 0 of rhenic acid, the following
    compounds:
    ; Methyl ester 5Z, 13E, 16Z-9-oxo-15R-oxi-1 6-fluoro-18,19,20-trinor-17-phenylprost-5,13,16-trienoic acid, Cc / Jj, - 81.4f C of J 3 5-492 (, EtOH); NMR (CBC1) {/ ppm: 3.64 (3N, s); 4.79 (1H, dvt); 5.37 (2H, m.); 5.82 (1H, d); 7.2 - 7.6 (5H, m.),
    0 Methyl ether 5Z, 13E, 16Z-9-oko--1 55-hydroxy-16-fluoro-18, 19,20-trinop-17-phenylprosta-5, 13-16-trienoic acid. lots, -40 ° j, 5-289.5 (,
    EtOH);
    5 Methyl ether 5Z, 13E, 16Z-9-oKCo-15K-hydroxy-1b-fluoro-18,19,20-trinor-17- (2-pyridyl) -prost-5,13,16-triene acid, 1 and -79,
    Methyl ether 5Z, 13E, 16Z-9-OKCO-0 -15K-oxy-16-fluoroprost-5,13,16-trienoic acid, o (j -41, 2 °}
    Methyl ether 5Z, 13E, 16Z-9-OKCO-i -155-hydroxy-1b-fluoro-18,19,20-trinor-17- (2-pyridyl) -prost-5,13,16-triene acid, t / jj -43.2.
    In addition, the product obtained in Example 1A is first oxidized, as well. then remove the protection in the 11th 15th position.
    5Z, 13E, 16Z-9-OKCO-11 o methyl ester is obtained (g 15K-dioxy 1 b-fluoro-18, 19,20-trinor-17-phenylprost-5,13,16-trnenoic acid) -93 , 3; S 3,5-52,4.
    Example 3. To a suspension containing 0.661 g of NaH (80% dis. Percy in mineral oil) in 92 ml of benzene, a solution containing 4.6 g of dimethyl (2-ok) is added dropwise. Q co-3-ftop) -hept-ZZ-enyl-Jofoconate in 40 ml of anhydrous benzene. The resulting mixture is stirred for 1 h. To the resulting gelatinous suspension, a solution of 5.58 g of gH-t (2 / V-formyl-3c /, 5c-dioxy-3-benzoate) -g iclopent-1-yl acetic acid is added in one step. kis- lots of lactone in 70 ml of anhydrous, benzene. The mixture is stirred for 20 minutes and then diluted with 60 ml.
    five
    0
    five
    ten
     (weight / volume) aqueous solution of NaHjPO. The organic phase is separated, washed with brine until neutral, then dried. The solvent is removed by trituration. The product obtained from C., (9.8 g) crystallized, twice its solution in hot methanol. The result is white crystals, which are collected by scrapping (6.25 g). The resulting product is pure e (- (3 -oxo-4-fluoro-oct-1 (E), 4 (Z) -dienyl) -3c), 5 ° C-dioxy-3-benzoate-3-cyclopent-1-yl acetic acid-g lactone, mp, 133-135 ° C, UJj, -96 °, (, CHClj).
     Example 4. A suspension of 0.104 g of NaH (80% dispersion in mineral oil) in 30 ml of anhydrous benzene is reacted with a solution containing 1.06 g of dimethyl- (2-oxo-3-fluoro-4-phenyl ) -but-ZE-enyl} -phosphonate in 10 ml of anhydrous benzene with the help of an external cooling E bath filled with dry ice and acetone. This reaction is completed within H hours. Then 1.5 ml of acetic acid are quickly added to the reaction mixture and allowed to warm to room temperature. Methanol is emptied. The solution is diluted with 20 ml of water and extracted twice with 50 ml of ethyl acetate. The resulting organic phase is rinsed with water and dried. The crude mixture of zpimeric alcohols was separated by high resolution liquid chromatography and using a preparative column filled with silica gel, by single-stage isocratic separation using a mixture consisting of ethyl acetate and cyclohexane in a ratio of 40; 60 as zluent.
    1.130 g of the less polar compound L- (2-bromo-3 (3) - -oxy-4-fluoro-5-phenyl-I (E), 4 (Z) 15 is obtained
    stirring and continue stirring i 25 pentadienyl) -3o, 5c-dioxybenzoate for 1 hour. A gel-like suspension is obtained, to which 0.61 g of fine N-bromosuccinimide is added at one time. After
    -cyclopent-N-yl acetic acid — g-β-lactone, i: o (j} -79.6 ° (, CHCl), and 1,600 g of the more polar compound W-C2 / 2g- (2-bromo-3 (K) -oxy-4-fluoro 15 -5-phenyl-1 (E), 4- (2) -pentadienyl) thistle, 0.82 g W- (2/3-formyl-3 , 5th (-di-., 5o / -dioxy-3-benzoic Cyclopente-1c / -yl acetic acid-g-lac tone 5 Go 7d-69.5 (, CHCl).
    Example 6. To a solution of 1.920 g of 35 (a- (2-bromo-s - (8) -oxy-4-fluoro-5 phenyl-1 (E), 4 (E) -pentadienyl) - 5 / - 7-cyclopent-1o / -yl acetic acid-11 lactone dioxy-3-benzoate in 30 ml of methanol was added 0.262 g 40 KjCOj. The mixture is stirred for
    hydroxy-3-benzoate) -cyclopent-1-yl} acetic acid-β-lactone in 20 ml of anhydrous benzene. The resulting mixture is stirred for 20 minutes, then diluted with 20 ml of a 6% (w / v) aqueous solution of NaH PO. The resulting organic phase is separated, washed until neutral and dried. The solvent is removed by evaporation.
    After purification on a column filled with silica gel, 0.97 g of CH- {C2 g- (2-bromo-3-oxo-4-fluoro-5 - -phensh1-1 (E), 4 (g) -pentadienyl) -34 / 5 5th; -dioxy-3-benzoate J-cyclopent-L-yl} yccyclic acid-d-lactone in the form of oil, td-Q-98 (, CHCi ;;).
    Example 5. A solution of 3.09 g of 1 of- {2 (2-bromo-3-oxo-4-fluoro-3-phenyl-l (E), 4 (2) -pentadienyl) -3, 5o-dioxy- 3-benzoate J-cyclopentyl. Acetic acid-β-lactone in 50 ml of ethylene glycol dimethyl ether is added dropwise to a cooled solution (-25 ° C) of 0.585 g of NaBHj in 70 ml of methanol. During the addition, the temperature of the reaction mixture is maintained in the range of -20 to -25 ° C
    3 h, then diluted with 40 ml of a 30% aqueous solution. and extracted three times with 50 ml of ethyl acetate. The organic phase obtained is washed
    45 with water and dry. The solvent is removed.
     Crude (2-bromide PShs) -oxooxy-4 -fop-5-phenyl-1 (E), 4 (g) -penta-dienyl) -Zo /, 5 (/ - dioxy j-cyclopent-1 -yl | acetic acid-j-lactone (1.25 g)
    gg is dissolved in 10ML of anhydrous CHjCL, and 0.856 ml of dihydropyran (BHP) and a catalytic amount of p-toluenesulfonic acid (approximately 0.006 g) are added. Stir the solution at
    55 at room temperature for 0.5 hour. A mixture of dark blue color is obtained. A: This solution is extracted with 50 ml of ethyl acetate, washed with brine and dried, and the solvent is removed. Raw residue
    using an external cooling bath filled with dry ice and acetone. This reaction is completed within H hours. Then 1.5 ml of acetic acid are quickly added to the reaction mixture and allowed to warm to room temperature. Methanol is emptied. The solution is diluted with 20 ml of water and extracted twice with 50 ml of ethyl acetate. The resulting organic phase is rinsed with water and dried. The crude mixture of zpimeric alcohols is separated by high-performance liquid chromatography and using a preparative column filled with silica gel, by single-stage isocratic separation using a mixture consisting of ethyl acetate and cyclohexane in a ratio of 40; 60.
    1.130 g of the less polar compound L- (2-bromo-3 (3) - -oxy-4-fluoro-5-phenyl-I (E), 4 (Z) are obtained
    Example 6. To a solution of 1.920 g (a- (2-bromo-s - (8) -oxy-4-fluoro-5 phenyl-1 (E), 4 (E) -pentadienyl) -5) -dioxy -3-benzoate 7-cyclopent-1o / -yl acetic acid-11 lactone in 30 ml of methanol was added 0.262 g of KjCOj. The mixture was stirred for
    3 h, then diluted with 40 ml of a 30% aqueous solution. and extracted three times with 50 ml of ethyl acetate. The organic phase obtained is washed
    water and dry. The solvent is removed.
    Crude (2-bromide PShs) -oxooxy-4 -fop-5-phenyl-1 (E), 4 (g) -penta-dienyl) -Zo /, 5 (/ - dioxy j-cyclopent-1 -yl | acetic acid-j-lactone (1.25 g)
    10 ML of anhydrous CHjCL is dissolved and 0.886 ml of dihydropyran (BHP) and a catalytic amount of p-toluenesulfonic acid (about 0.006 g) are added. Stir the solution at
    room temperature for 0.5 h. A mixture of dark blue color is obtained. This solution is extracted with 50 ml of ethyl acetate, washed with brine and dried, and the solvent is removed. Raw residue
    chromatographed on a column filled with silica gel; a mixture consisting of cyclohexane and ethyl acetate in a 70:30 ratio is used as the eluent. As a result, 0.650 g of pure 1о (/} - (2-bromo-3 (5) -oxy-4-fluoro-5-phenes-1-1 (E), 4 (g) -pentadienyl) -C, 5 ° / dioxid-3,
    3-bis-tetrahydropyranyl simple Q th ether.
    the alkaline phases are combined, acidified to pH 5, and then extracted with diethyl ether and n-pentane, in a ratio of 1:11
    This gives 0.67 g of 5Z, 16Z-9c /, 11 / - -15K-trioxy-16-fluoro-18,19,20-trino-17-phenylprost, 5,16-diene-13-inoic acid 11,15- bis-tetrahydropyran
    th cyclopent-N-yl ester of acetic acid-y-lactone.
    Example 7 In a nitrogen atmosphere, 2.49 ml of a 20% solution of diisobutylammonium (DIBA) hydride in toluene was added over 15 minutes to a stirred solution of 1c / - {tZ / b (2-bromo-3 (8) -oxy) -4-fluoro-5-phenyl-1 (E), 4 (2) -pentadienyl) -Zo, 5o-dioxy-3,3-bis-tetrahydropyranyl ether -cyclopent-N-yl-acetic acid Tbi-j- varnish then (1.120 g) in 10 ml of anhydrous toluene, cooled to -70 C. Stirring is continued for 30 minutes. The reaction mixture is then treated with 2H-isopropanol in toluene, after 10 minutes heated to 0-2 ° C and treated with 1.5 ml of water, 2 g of sodium sulfate (anhydrous) and 2.5 targets. Example 9. A solution of the crude product according to Example 8 (0, 67 g) in 15 ml of acetone is treated for 8 hours with 16 ml of aqueous 0.2N.
    15 solution of oxalic acid. After removing the acetone under vacuum, the aqueous phase is extracted with diethyl ether and the combined ether extracts are washed with water until neutral and then dried and evaporated to dryness.
    The residue obtained is chromatographed on silica gel; a mixture consisting of
    25 methylene chloride and ethyl acetate in the ratio of 80:20. Obtain 0.3 &amp; 0 g pure 5Z, 16Z-9 (/, 11 of-15K-trioxy-16-flu-18,19,20-trinor-17-phenylprost-5 1
    35
    40
    -diene-13-inic acid, CIs} p-31.5 and R, and then filtered. Filtrate condensate (, EtOH); mass spectrum: trimetip- soar to dryness in vacuum. Silicon derivative, m / e: 690,
    1.050 g of (J- (2-bromo-601, 5T2, 423. -34s) -oxy-4-fluoro-5-phenyl-1 (E), 4 (2) -pentadienyl) -Zo (, 5bioxy-3 , 3-bis-tetrahydropyranyl ether-cyclopent-1 cbyl j-acetaldehyde-y-hemiacetal.
    Example 8. Under an argon atmosphere, a solution of 1.903 g of triphenyl (4-carboxybutyl) phosphonium bromide in 7.5 ml of anhydrous dimethyl sulfoxide was added in portions of 0.965 g of potassium t-butylate, mixed until a purple solution of ylide was obtained and
    0.750 g of 1O (-i2-p- (2-bromo. -3 (5) -oxy-4-fluoro-5-fench1-1 (E), 5Z, 13E, 16Z-9-Oxo-15R-oxy) are added -16-4 (Z) 7-pentadienne) -Cc, 5o-dioxy-3,3 - -fluoro-18,19, 20-trinor-17- (2-pyri. -Bis-tetrahydropyranyl: ether -cyclopent-acetaldehyde- -y-hemiacetal dissolved in 7.5 ml of anhydrous dimethyl sulfoxide. The resulting reaction mixture was stirred for 3 hours at room temperature and then placed in an ice bath and diluted with 70 ml of ice-water. The alkaline aqueous phase was extracted with diethyl ether and ether extracts re-rinsed with 1N sodium hydroxide solution . Received water
    45
    Similarly receive the following products:
    5Z, 1ZE, 16Z-9-OKCO-15R-OKCH-16-fluoroprost-5,13,16-trienoic acid, (/ JB -42,4 j
    5Z, 13E, .16Z-9-Oco-15R-oxy, 16-fluoro-18,19,20-trinor-17-phenyl () osta-5,13,16-triene acid, Ce / Jjj -82, 7 ° i
    5Z, 13E, 16Z-9-Okco-15o-ox-16- -fluoro-18,19,20-trinor-17-phenylprost -5,13,16-trienoic acid, t o (J d -41%
    50
    Dil) -simple-5,13,16-trienoic acid, -80,5 ° i
    5Z, 13E, 1bg-9-Oxo-15o (-oxy-16-fluoro-18,19,20-trinop-17 - () I-dyl) -prost-5,13,16-trienoic acid, UJi - 44.5.
    Example 10. To 0.751 g of methyl 55th 5Z ether, 13E, 16Z-9of, 11o / -15R-. -trioxy-16-fluoro-18,19,20-trinor-17- - (2-fursh1) -prost-5,13,16-trienoroy acid 9,15-bis-dimethyl-t-butylsilyl ether 11 benzoate.
    th simple ether.
    the alkaline phases are combined, acidified to pH 5, and then extracted with diethyl ether and n-pentane, in a ratio of 1:11
    Obtain 0.67 g of 5Z, 16Z-9c /, 11 / - -15K-trioxy-16-fluoro-18,19,20-trinor-17-phenylprost-5,16-diene-13-inoic acid 11,15- bis-tetrahydropyrano Example 9: A solution of the crude product from example 8 (0.67 g) in 15 ml of acetone is treated for 8 hours at 16 ml of water 0.2 n.
    oxalic acid solution. After removal of the acetone under vacuum, the aqueous phase is extracted with diethyl ether and the combined ether extracts are washed with water until neutral, then dried and evaporated to dryness.
    The residue obtained is chromatographed on silica gel. A mixture consisting of
    methylene chloride and ethyl acetate in the ratio of 80:20. Obtain 0.3 &amp; 0 g pure 5Z, 16Z-9 (/, 11 of-15K-trioxy-16-fluoro-18,19,20-trinor-17-phenylprost-5 16
    601, 5T2, 423.
    5Z, 13E, 16Z-9-Oco-15R-oxy-16-fluoro-18,19, 20-trinor-17- (2-pyri
    Similarly receive the following products:
    5Z, 1ZE, 16Z-9-OKCO-15R-OKCH-16-fluoroprost-5,13,16-trienoic acid, (/ JB -42,4 j
    5Z, 13E, .16Z-9-Oco-15R-oxy, 16-fluoro-18,19,20-trinor-17-phenyl () osta-5,13,16-triene acid, Ce / Jjj -82, 7 ° i
    5Z, 13E, 16Z-9-Okco-15o-ox-16- -fluoro-18,19,20-trinor-17-phenyl-prosta-5,13,16-trienoic acid, t o (J d -41%
    5Z, 13E, 16Z-9-Oco-15R-oxy-16-fluoro-18,19, 20-trinor-17- (2-pyri
    Dil) -simple-5,13,16-trienoic acid, -80,5 ° i
    5Z, 13E, 1bg-9-Oxo-15o (-oxy-16-fluoro-18,19,20-trinop-17- () I-yl) -process-5,13,16-trienoic acid, UJi -44.5.
    Example 10. To 0.751 g of methyl ester 5Z, 13E, 16Z-9of, 11o / -15R-. -trioxy-16-fluoro-18,19,20-trinor-17- - (2-fursh1) -prost-5,13,16-trienoroy acid 9,15-bis-dimethyl-t-butylsilyl ether 11 benzoate.
    dissolved in 7 ml of anhydrous methanol, 0.166 g is added, the mixture is stirred for 6 hours. This reaction is then quickly interrupted by the addition of 70 ml of ice and extracted with ethyl acetate. The organic phase is washed with water and dried. The solvent is removed in vacuo. The crude residue is chronographed on silica gel using a mixture consisting of ethyl acetate and n-hexane in a ratio of 20:80 as eluent.
    This gives 0.453 g of pure methyl ester 5Z, 13E, 16Z-9 /, 11 / -15R- -trioxy-1b-fluoro-18,19,20-trinor-17- (2-furylprost-5,13,16-trieno - the acid of 9,15-bic-dimethyl-tert-butyl-1-ethyl ether. This derivative is dissolved in 3 ml of CHjCl and a paste consisting of.} 0.266 g of pyridinium chlorochromate in 5 ml of CHjCl is added. The mixture is stirred for 1 h and then add 40 ml of diethyl ether. The black solid material is filtered. The organic phase is distilled. A crude residue is obtained (0.383 g) o representing methyl ester. 5Z, 13E, 1bg-9o -15E-dioxy 11-oxo- 6-fluoro-18,19,20-trinor-17- (2-furyl) -prost-5,13,1b-trienoic acid 9,15 bis-dimetsl-tert butilsililovy simple ether Syro 11-oxo- the derivative is dissolved in 3 ml of a 30% mixture of acetonitrile and a 40% aqueous solution of hydrogen fluoride. The resulting solution is stirred for 2.5 h.
    To this solution, 50 ml of CHCl 3 and 10 ml of water are added. The organic phase is separated, washed and dried. The rast is removed under a vacuum. The crude product obtained is purified by flash chromatography on silica gel, using a mixture consisting of ethyl acetate and i-hexane in a ratio of 70:30 as eluent, to give .0.173 g of pure methyl 52.13E, 16g-9 / -15K-dioxy-11-oxo-16-fluoro-18,19,20-trinor-17- (2-furyl) -prost-3, 13,16-trienoic acid, m.p. .
    Example 11. Rast the thief from .0.470 g of methyl ester 5Z, 13E, 16Z-9e /, 1 N- -15R-trioxy-16-fluoro-18,19,20-trinor-17-phenylprost-5,13,16 -trienova
    Acids of 15-tetrahydropyric ether in 25 ml of acetone are cooled to -30 ° C and then treated with 1.2 ml
    Jones reagent that is added. within 4 min. The reaction mixture thus obtained is further stirred at 15 minutes and then heated to and kept at this temperature for 15 minutes. The mixture is allowed to warm to room temperature, and then it is diluted with 100 ml of benzene, the organic phase is washed with a saturated solution (N114) 2504 until neutral, dried and evaporated to dryness.
    This gives 0.450 g of a mixture consisting of 5Z, 13E, 16Z-9 / - -15R-diox-11-oxo-16-fluoro-18 methyl ester, 19.20
    -trinor-17-phenylprost-5,13,16-triekova acid 15-tetrahydropyranic acid. ether and methyl ether 5Z, 1-ЗЕ, 16Z-16-otorop-9-occo-11 / 15R-dioxy-18,19,20-trinor-17-phenylpro
    ta-5,13,16-triene acid 15-tetrahydropyranyl ether. This solution of the crude mixture in 25 ml of acetone is treated with 25 ml of 20% aqueous solution of acetic acid
    at 40 ° C for 2 hours. The resulting solution is extracted with diethyl ether, washed until neutral, dried, and the two compounds are separated by chromatography on silica gel using a mixture of ethyl acetate and n-hexane in a 70 ratio as eluent: 30o
    As a result, 0.136 g of pure 5Z-13E methyl ester, 6Z-9o (α-dioxy-11-oxo-16-fluoro-18, 19.20-trinor-17-phenylprost-5, 13,16-trienoic acid, t. mp 72 C, and 0.121 g of pure methyl ester 5Z, 13E, 16Z-9-.-oxo-11a / -15I-dioxy-16-fluoro-18.19,
    20-trinor-17-phenylprost-5,13,16-trienoic acid, m.p. 45 ° C.
    Similarly receive the following products:
    5Z, 13E, 16Z-9o / -15R-Dixy-11-oco-16-fluoro-18, 19,20-trinor-1 7-cklohexylprost-5,13,16-trienoic acid
    5Z, 16Zr9o 15R-Dioxy-11-oco-16-fluoro-18,19,20-trinor-17-cyclohexylprost-5, 16-diene-13-inova acid, 5Z, 13E, 16Z-9o / -15R- Dioxy-11-occ6- -16-fluoro-18,19,20-trinor 17-phenyl is simple-5,13-16-trienoic acid;
    5Z, 16Z-yo (-15K-Dioxy-11-oxo-16-fluoro-18,19,20-trinor-17 phenylprosta-5,16-diene-13 inic acid;
    52,13E, 1bg-9sM5K-Dioxy-I-oxo-16-fluoro-18,19,20-trinor-17- (2-furyl) -prost-5,13,16-tryyloic acid}
    5Z, 16Z-9of-15K-Dioxy-11-oxo-16-fluoro-18,19,20-trinor-17- (2-furyl) is simple-5,16-diene-13-inova acid,
    5Z, 13E, 16Z-9rf-15R-Dioxy-11-oxy-16-fluoro-18,19,20-trinor-17- (2-cyanyl) -prost-5,13,16-trienoic acid;
    5Z, 16Z-9o 15R-Dioxy-11-oco-16- -fluoro-18,19,20-trinor-17- (2 -tyensh1) - -prost-5,16-diene-13-inic acid.
    Example 12. A solution of 0.40 g of 5Z, 13E, 16Z-9 /, 1 N-15K - trioxy-1 b-fluorine -18,19,20-trinor-17-fensh1Prosta-5, 13,16-trienoic acid in 15 ml of diethyl ether is treated with 1.1 ml of 1N. solution of diaeomethane. The resulting yellow solution is stirred for 15 minutes and then evaporated to dryness.
    0.42 g of pure methyl ester of 5Z, 13E, 16Z-9of, 11o is obtained (-15R-transioxy-16-fluoro-18,19,20-trinor-17-phenylproduct-5. (13,1.6-trienoic acid with (Jd, -27.0 °; from Jiff-146.0, ethanol).
    Similarly, used as starting compounds 5Z, 13E, 16Z-9o (, 1 Н-15 S-triok si-18,19,20-trinor-16--fluoro-17-phenylprost-5,13,16-trieno Vuya, acid, get
    Methyl ester 5Z, 13E, 16Z-9 jf, 1Y-15K-trioxy-1b-fluoro-18,19,20-tripinop -1 7- (2-thienyl) -prost-5,13,16-triene acids, Ce Jj)
    Methyl ester 5Z, 16Z-9o /, 11o / -15R- -trioxy-16-fluor-18, 19.20-trinor-17- - :( 2-thienyl) -prost-5.16-diene-13-yno - howl acid, fojj-19.2;
    Methyl ester 5Z, 13E, 16Z-9-OKCO-11 about -15R-diox-16-fluoroprost-5,13, 16-trienoic acid,) 80,5 J
    Methyl ester 5Z, 13E, 16Z-9-OKCo - -11 s / t15I-dioxy-16-fluoro-20-methylprosta-5,13,16-trienoic acid, -72 ° J
    Methyl ester 5Z, 13E, 164-9-oxo--110 / -15K-dioxy-16-fluoro-20-e-tylprosta-5,13,16-trienoic acid, Co d -70.5%
    Methyl ester 5Z, 13E, 16Z 9-oKco- -1 Н -15К-dioxi-16-.fluor 18,19,20

    YU
    15
    20 25
    ZO
    35
    40
    five
    0
    five
    -trinor-17-phenylprost-5,13,16-trienoic acid, -93.3 °;
    Methyl ester 5Z, 13E, 16Z-9-oKco--1Y-15R-diox-16-fluorop-18,19,20- -trinor-, 17- (2-furyl) -prost-5,13,16- - trienoic acid, C d-81 °;
    Methyl ester 5Z, 13E, 16Z-9-ox-1-1-1 5R-dioxy-16-fluoro-18,19,20- -trinor-17- (2-thienyl) -prost-5,13, 16- trienoic acid, C Jp-38 °.
    Example 13. CuCl in the amount of 0.017 g is added to a solution of 1.373 g of dicyclohexylcarbodiimide (DCCX in 0.661 g of 2-ethoxyethanol, cooled to 0 ° C.
    The resulting mixture was stirred for 1 hour at 0 ° C, and then allowed to warm to room temperature. The mixture is kept at this temperature for 24 hours, diluted with 5 ml of n-hexane, filtered on silica gel and washed with n-hexane. The solvent is removed. 1.00 g of pure dicyclohexyl-2-ethoxyethyl isopropyl is obtained. This product is dissolved in
    10 ml of tetrahydrofuran and added to a solution of 1 g of 5Z, 13E, 16Z-9 (/, 11cl-15R-tripioxy-16-fluoro-18, 19,20-trinor-17-phenyl) osta-5,13,16- trienoic acid in 10 ml of anhydrous tetrahydrofuran. The resulting mixture is heated to and kept at this temperature for 6 hours. The solvent is removed under vacuum. The resulting crude product is purified on silica gel using a mixture consisting of ethyl acetate and n-hexane (70:30) as eluent.
    Pure 2-ethoxyethyl ester of 5Z, 13E, 16Z-9p, 1 1 of-15R-triphoxy-16-fluoro-18,19,20-trinor-17 enyl-simple-5,13,16-trienic Zolota is obtained (0.925 d), 4 ° (, CHCl,).
    Similarly, the following 2-ethoxyethyl esters are obtained:
    2-Ethoxyethyl ester 5Z, 13E, 16Z-9o /, 11 o -15R-tripioxy-16-fluoroprosta-5,13,16-trienoic acid, -W, ° i
    2-Ethoxyethyl ester 5Z, 16Z-9o (,
    11of-15R-trichroxy-16-fluoropropotar5,16-dien-13-inic acid, Co (J3j-t8 j
    2-ETOKSIETSH10VYY efur 5Z, 13E, 16Z-9 e /, 11 oM 5K-trioxy-16-fluoro-18,19,20-trinor-17-cyclohexylprost-5,13,16-trienoic acid, dl J at -15 °}
    2-Ethoxyethyl ester 5Z, 16Z-9c (, 11vt-15R-tripioxy-16-ftorop-18,19,2013
    -trinor-17-cyclohexylprost-5,16- -diene-13-inoic acid-2-e tox, -16,8 i
    2-Ethoxyethyl ester 5Z, 16Z-9o /, 11o / -15K-trioxy-16-fluoro-18,19,20-trinor-17-phenylprosta-5,16-di-13-inoic acid-2-e current si, -20,
    2-Ethoxy ether 5Z, 13E, t6Z-. 10 sulfonylamide, f o Jj) -16.5 (, -9c, 1 L-15E-trioxy-16-fluoro-18, 19.20-CHClj). -trinor-17- (2 -fursh1) -simply-5.13, 16-trienoic acid-2-ethoxy, Gs / J -19.5 °.
    2-Ethoxyethyl ester 5Z, 16Z-9of, 1Ы-15К-trioxy-16-fluoro-18,19,20-trinor-17- (2-furyl) -prost-5,16-dien-1E-inoic acid , tof J jj-30,7;
    2-Ethoxyethyl ester 5Z, 13E, 16Z In the same way, the following N-methanesulfonylamide derivatives are obtained:
    , 16Z-9o, 1 and -15E-Trioxy-15 -16-fluoro-18,19,20-trinor-17- (3 -iso-xazolyl) -prost-5,13,16-trienoic acid L-methanesulfonylamide, -n -16
    5Z, 16Z-9, 11o-15R-Trioksi-16-otor-9llc, 11o-15R-trity-16-ft-18, i9,20-20 -18,19,20-trinor-17- (3 -isoxazolyl) -,
    -trinor-17- (2 -terium) simple-5.13, 16-trienoic acid, HS /} l -25 °.
    2-Ethoxyethyl. Ether 5Z, 16Z-9., 1 N-13K-trioxy-16-fluoro-18 ,. 19,20-trinor-17- (2-tsikyl) -simply-5,16-dien-i3-inoic acid-2-et. , TofJa, -20.7. .
    Example 14. A solution of 2,323 g of potassium t-butoxide in 15 ml of anhydrous dimethyl sulfoxide is mixed in. an atmosphere of anhydrous argon and then, while cooling on a water bath, 4.33 g of G4- (methanesulfonylaminocarbonyl) butyl} triphenylphosphonium bromide is added. The temperature of the resulting reaction mixture was maintained at 30 ° C. Addition is complete after approximately 13 minutes. Then to the mixture was added 15 ml of (3Fg) -Oxy-4-fluoro-5-furyl- (E), 4 (Z) -Phentadienyl) -3C3 /, 3C (-dioxy-3,3 -bis - -tetrahydropyranyl ether} - -cyclopene t-1; / - yl-acetaldehyde-1-, luacetal in 13 ml of anhydrous dimethylsulfoxide. This reaction is completed after approximately 1 hour. Then the reaction mixture is quickly poured water to stop further reaction. The resulting mixture is extracted with distil ether. The solvent is removed and the crude product is chromatographed on silica gel using a mixture consisting of these as eluent. lacetate and n-hexane in the ratio of 1s1, the result is 1.93 g of pure 5Z, 13E, 16Z- -9olt 11o (-13K-trioxy-16-fluoro-18, 19,20-tripiop-17- ( 2 -pypsh I) -prosta-3, 13,16-trienoic acid p methanesulfonylprost-3, 16-diene-13-IIOBOY acid
    N-methanesulfonyl, SJi) -17.3 j 3Z, 13E, 16Z-9of, 11o-13K-Trioxy-16-fluoroprost-3, 13,16-trienoic acid, 25l H-methanesulfonylamide, Go Jjp 3Z, 16Z-9o /, 1 to (-1 LC-Trioxy-16-fluoro-simple-3,16-diene-13-inoic acid N-methanesulfonylamide, SJD -19 °;
    3Z, 13E, 16Z-9or, 11o (-13E-Trioxy-16-30-fluoro-20-methylprost-3, 13,16-trienoic acid N-methanesulfonylamide, Cci D-22 °
    3Z, 16Z-9 ° C, 11 of-13K-Trioxy-16-fluoro-20-methylprost-3, 16-diene-13-inoic 35 acid N-methanesulfonyl amide, Go (Jj; -18.5 °;
    3Z, 13E, 16Z-9o (, 11fl -15R-Tripioxy-16-fluoropro-20-ethylprostate-5, 13,16-trienoic acid N-methanesulfonylamide, 40 Cc JjD-21.8 °;
    3Z, 16Z-9o, 1 N-15K-Trioxy-16-fluoro-20-ethylprost-5,16-diene-13-inoic acid N-methanesulfonyl amide, o1 -22.3 °;
    45 3Z, 13E, 16Z-9of, 11o (-13K-Trioxy-16-fluoro-18,19,20-trinor-17-cyclohexyl-simple-3,13,16-trienoic acid N-: -methanesulfonyl amide, L j) -17,
    3Z, 16Z-9o, 11 / -13K-Trioxy-16-fluoro-50 -18.19 19 20-trinop-17-cyclohexylproxy-3, 16-diene-13-inoic acid N-me-, sulfo NIL amide, fctj -13,
    55
    3Z, 13E, 16Z-9.1Y-15R-Tripioxy-16-β-thop-18, 19,20-trinor-17- (3-chlorophenyl) -prost-3,13,16-trienoic acid
    N-methanesulfonyl, So (DC-23, 7 °;
    3Z, 13E, 16Z-9o /, 1Ы-15R-Trioksi-16- -fop-18, 19,20-trinor-17- (4-trifluor144207014
    amide-11,15-bis-tetrag1-spiranyl ether. As a result of deprotection in 0.5 g of the obtained product in accordance with the method of. Example 9, 0.3 g of pure 5Z, 13E, 16Z-9o /, 11 / -15K-trioxy-16-fluoro-18,19,20-trinor-17- (2-furSH1) prostate-5 is obtained , 13.1b-trienoic acid N-methanesulfonylamide, f o Jj) -16,5 (, CHCl j).
     The following N-methanesulfonylamide derivatives are prepared analogously:
    , 16Z-9o, 1, and-15E-Trioxy-16-fluoro-18,19,20-trinor-17- (3-iso-xazolyl) -prost-5,13,16-trienoic acid L-methanesulfonylamide, - n -16
    simple-3,16-diene-13-IIOBOY acid
    N-methanesulfonyl, SJi) -17.3 j 3Z, 13E, 16Z-9of, 11o-13K-Trioxy-16-fluoroprost-3, 13,16-trienoic acid H-methanesulfonylamide, Go Jjp 3Z, 16Z -9o /, 1 to (-1 LC-Trioxy-16-fluoro-simple-3,16-diene-13-inoic acid N-methanesulfonylamide, SJD -19 °;
    3Z, 13E, 16Z-9or, 11o (-13E-Trioxy-16-fluoro-20-methylprost-3, 13,16-trienoic acid N-methanesulfonyl amide, Cci D-22 °
    3Z, 16Z-9 ° C, 11 of-13K-Trioxy-16-fluoro-20-methylprost-3, 16-diene-13-inoic acid N-methanesulfonylamide, Go (Jj; -18.5 °;
    3Z, 13E, 16Z-9o (, 11fl -15R-Tpiocsi-16-fluorop-20-ethyl-prostate-5, 13,16-trienoic acid N-methanesulfonylamide, Cc JjD-21.8 °;
    3Z, 16Z-9o, 1 N-15K-Trioxy-16-fluoro-20-ethylprost-5,16-diene-13-inoic acid N-methanesulfonyl amide, o1 -22.3 °;
    3Z, 13E, 16Z-9of, 11o (-13K-Trioxy-16-fluoro-18,19,20-trinor-17-cyclohexyl-simple-3,13,16-trienoic acid N-: -methanesulfonyl amide, YJ ) -17,
    3Z, 16Z-9o, 11 / -13K-Trioxy-16-fluoro-18.19, 20-trinop-17-cyclohexyl-propoxy-3, 16-diene-13-inoic acid N-methane sulfo NILE amide, fctj -13,
    3Z, 13E, 16Z-9.1Y-15R-Tripioxy-16-β-thop-18, 19,20-trinor-17- (3-chlorophenyl) -prost-3,13,16-trienoic acid
    N-methanesulfonyl, So (DC-23, 7 °;
    3Z, 13E, 16Z-9o /, 1Y-15R-Tpiocsy-16-β-fop-18, 19,20-trinor-17- (4-trifluoromethylphenyl) -prost-5,13,16-triene acid N-methanesulfonyl amide, to / Jl -22.9 °;
    5Z, 13E, 16Z-9c, 1U-15R-TpHOKCH-16-fluoro-18,19, .20-trinor-17-phenyl-prosta-5,13,16-trienoic acid N-methanesulfonyl amide, Cdl 1 -24}
    5Z, 16Z-9of, 1 L-15K-Trioxy-16-fluoro 5Z, 13E, 16Z-9of, 11 d -15K-Trioxy-1 6-fluoro-20-methylprosta-5,13,16-trienoic acid, r “J 17-20; .
    5Z, 13E, 16Z-9 3, 11o 15R-Trpnokoksi-16-ftop-20-ethylprostate-5, 13, 16-trienoic acid, G 7 l -20,8 ° j
    5Z, 13E, 16Z-9 U, 11of-15R-Tripioxy-16-fluoro-18,19,20-trinor-17-cyclohexyl
    -18,19,20-trinor-17-fensch-simple-5,16-10 is simple-5,13,16-trienoic acid.
    CofJj} -17,9
    -diene-13-inic acid N-methanesulfonylamide, Co Jj-20.7;
    5Z, 13E, 16Z-9o /, l N-15E-Trioxy-16-fluoro-18,19,20-trinor-17- (3-furyl) - -prost-5,13,16-trienoic acid 15 N- methanesulfonamide, and (j}
    5Z, 16Z-9of, 11o-15R-Trioksi-16-otor-18,19,20-trinop-17- (3-yrshl) -propos-5, 16-diene-13-inoic acid N-methanesulfonylamide , Co (Ju-20Pjf20
    5Z, 13E, 16Zr9o, 1Y-15R-Tpioksi-16- -fluoro-18,19,20-trinor-17- (2-thien0l) -prost-5,13,16-trienoic acid N- -methanesulfonylamide,) 27®;
    CofJj} -17,9
    5Z, 13E, 16Z-9 of, 1 L-15R-Trioxi-16- | -fluoro-18,19,20-trinor-17- (3-chlorophenyl) -prost-5, 13,16-trienoic acid ., Go (7d -24.5 °,
    5Z, 13E, 16Z-9of, 1 and-15R-Tpioksi-16-fluoro-18,19,20-trinor-17- (4-trifluoromethylphenyl) -prost-5,13,16-trienoic acid, S JD -23,
    5Z, 13E, 16Z-9o (, 11oM5R-Tpioksi-16-ftop-18,19,20-trinop-17- (2-furyl) - -prost-5,13,16-trienoic acid, Is -19 , 5 ° -,
    5Z, 13E, 16Z-9o, 11s (-15R-Trioxi-165Z, 16Z-9o (, 11 s (-15R-Trioxi-16-otor-25-fluoro-18,19,20-trinor-17- (2 -thienyl) -18, 19,20-trinor-17- (2-thienyl) -product-ta-5,16-dione-13-inoic acid N-methanesulfonylamide, Guo T) -25 °;
    5Z, 13E, t6Z-9 3 /, 11c / -15K-Trioxy-16-fluoro-18,19,20-trinor-17- (2-pyrrolyl) simple-5,13,16-trienoic acid N-methanesulfonyl, tc / H-18,
    -simple-5,13-16-trienoic acid, Cc / Ji -18,8 ° i
    5Z, 13E, 16Z-90 /, 11th 15R-Tpioksi-16- -fluoro-18,19,20-trinor-17- (2-pyrrollesh1) -prost-5,13-16-trienoic acid, CofJs -IS;
    5Z, 13E, 16Z-9 of, 11of-15R-Tripioxy-16-fluoro-18,19,20-trinor-17- (W-pyri-. Dil) -prost-5,13,16-triene acid 35 you, JB-15.5 ° i
    5Z, 16Z-9o, 11 o / -15R-Tripioxy-16-fluoro-18,19,20-trinor-17- (2-pyrrolesh 1; -: -prost-5,1b-diene-13-inoic acid M - M. tetanesulfonyl, C) ID 1,5,
    5Z, 13E, 16Z-9 5 /, 11of-15R-TpHOKCH-16-fluoro-18,19,20-trinor-17- (3-pyri-.v dsh1) - simple-5.16-di- 13-inoic acid N-methanesulfonylamide, Cd t
    Example 15. A solution of 0.60 g of 5Z, 13E, 16Z-9 (, 11C / -15R-tripioxy-16-fluoro-18,19,20-trinor-17-phenylpro-sta-5,13,16-triene Acids in 5 ml of Zanol are treated with 15 ml of a 0.1N sodium hydroxide solution. The alcohol is removed under vacuum and the aqueous solution is lyophilized to give 0.64 g of anhydrous 5Z, 13E, 16Z-9o sodium salt (1Y-15R-trichloride). -16-ftor-18,19,20- -trinor-17-phenylprost-5,13,16-trienoic acid in the form of white powder,, -22 (, ethanol).
    Similarly, sodium salts of the following compounds are obtained:
    5Z, 13E, 16Z-9 (/, 1 1oi-15R-Tripioxy-16-fluoroprost-5,13,16-trienoic acid,: U ID -19,5 ° -, ....

     simple-5,13,16-trienoic acid.
    CofJj} -17,9
    5Z, 13E, 16Z-9 of, 1 L-15R-Trioxi-16- | -fluoro-18,19,20-trinor-17- (3-chlorophenyl) -prost-5, 13,16-trienoic acid ., Go (7d -24.5 °,
    5Z, 13E, 16Z-9of, 1 and-15R-Tpioksi-16-fluoro-18,19,20-trinor-17- (4-trifluoromethylphenyl) -prost-5,13,16-trienoic acid, S JD -23,
    5Z, 13E, 16Z-9o (, 11oM5R-Tpioksi-16-ftop-18,19,20-trinop-17- (2-furyl) - -prost-5,13,16-trienoic acid, Is -19 , 5 ° -,
    5Z, 13E, 16Z-9o, 11s (-15R-Tripioxy-16-fluoro-18, 19.20-trinor-17- (2 -thienyl)
    -simple-5,13-16-trienoic acid, Cc / Ji -18,8 ° i
    5Z, 13E, 16Z-90 /, 11th 15R-Tpioksi-16- -fluoro-18,19,20-trinor-17- (2-pyrrollesh1) -prost-5,13-16-trienoic acid, CofJs -IS;
    5Z, 13E, 16Z-9 of, 11of-15R-Tripioxy-16-fluoro-18,19,20-trinor-17- (W-pyri-. Dil) -prost-5,13,16-triene acid 5 you, JB-15.5 ° i
    5Z, 13E, 16Z-9o, 1Y-15R-Tpioksi-16-fluoro-18,19,20-trinor-17- (2-pyrazinyl) -proet-5,13,16-triene acid, CofJD- 33;
    0 .5Z, 13E, 16Z-9o, 1Y-15R-Tpiocsy-16-β-fop-18,19,20-trinor-1 7- (3-izoksa zolyl) -prost-5,13,16-triene acid , pillboxes, With JB-I.
    Example 16. In an argon atmosphere of 5, a solution of 1.965 g of potassium t-butylate is added to a solution of 1.903 g of triphenyl (4-carboxybutyl) phosphonium bromide in 7.5 ml of anhydrous dimethyl sulfoxide. Stir until a Q. purple solution of ylide is obtained. Then, 0.750 g of (- (3 (8) -oxy-4-fluoro-5-phenyl-1 (E), 4 (I) -pentadienyl) -3O, 5a-dioxy-3,3 -bis bis-tetrahydropyranyl J-cyclopent-N-yl j-acetaldehyde-β-j-hemiacetal simple ether dissolved in 7.5 ml of anhydrous dimethyl sulfoxide. The resulting reaction mixture is stirred for 3 hours at room temperature, then placed in an ice bath and diluted 70 ml of ice water The alkaline aqueous phase is extracted with ethyl ether. The ether extracts are re-washed with 1N sodium hydroxide solution. The resulting aqueous alkaline phases are combined, sour added to pH 5 and then extracted with diethyl efiromi n-pentane in a ratio of 1: 1.
    Obtain 0.67 g of 5Z, 13E, 16Z-9c, W-15K-trioxy-16-fluoro-18,19,20-triphor-17-phenylprosta-5,16-diene-13-inoic acid 11 , 15-bis-tetrahydropyranic ether.
    Example .17. A solution of the crude product (0.67 g) of example 1 in 15 ml of acetone is treated for 8 hours at 35 ° C. 16 ml of aqueous 0.2N.
    oxalic acid solution. After removal of the acetone under vacuum, the aqueous phase is extracted with diethyl ether and the combined ether, the extracts are washed with water until neutral, and then dried and evaporated to dryness. The residue obtained is chromatographed on silica gel. A mixture consisting of methylene chloride and ethyl acetate in a ratio of 80:20 is used as eluent.
    0.340 g of pure 5Z, 13E, 16Z-9o, 11 o -15K-trioxy-16-fluoro-18, 19,20-tripor-17-phenylprosta-5516-diene-13-inoic acid, 26 (EtOH) are obtained. .
    Example 18 A solution of 0.40 g of 5Z, 13E, 16Z-9o, 11s / -15K-trioxy-16-α-fluoro-18519.20-trinor-1 U-phenylproduct -5,13,16-trienoic acid, in 15 ml of diethyl ether is treated with 1.1 m 1 n. diazomethane solution. The resulting yellow solution is stirred for 15 minutes and then evaporated to dryness.
    Obtains 0.42 g of pure methyl ester 5Z, 13E, 16Z-9o, 11йf-13R-trioxyl-16-fluoro-18,19,20-trinor-17-fensh-simple -5,13,1b-trienev .. acids, CO / JD -27.0 i D 36J-146.0 ° (, ethanol).
    Example 19. A solution of the crude product (0.67 g) of example 1 in 15 ml of acetone is processed for 8 hours at 35 ° C with 16 ml of aqueous 0.2N. oxalic acid solution. After removal of the acetone under vacuum, the aqueous phase is extracted with diethylether. The combined ether extracts are concentrated.
    r o
    five
    0
    50
    S
    0 5
    0
    five
    wash with water until neutral, and then dry and evaporate to dryness. The residue obtained is chromatographed on a slice gel. A mixture consisting of methylene chloride and ethyl acetate in the ratio 80:20 is used as eluent.
     0.340 g of pure 3Z, 13E, 16Z-9o, 1 W-15K-trioxy-, 1 b-fluoro-18, 19,20-trinor-17-phenylprosta-5,1,16--trienoic acid, Cof 1 jf are obtained 26 (, EtOH).
    Example 20. A solution of 0.40 g of 5Z, 13E, 16Z-9 /, 1Ы-15R-tripioxy-16-β-ftop-18, 19,20-trinor-1 7-phenyl-prosta-5,13-16-trienoic acid 1.1 ml of 1N is treated in 15 ml of diethyl ether. diazomethane solution. The resulting yellow solution is stirred for 15 minutes and then evaporated to dryness.
    Obtain 0.42 g of pure methyl ester 5Z, 13E, 16Z-9of, 11ol: -15R-tripioxy-16-fluorop-18,19,20-trinop-17-phencol-process-5,13,16-triene acids, ofjj, -27 ,,; -146.0 ° (, ethanol).
    The compounds of formula (I) and in particular 9o-oxy derivatives are characterized by significant luteolytic activity, so they can be used to regulate pregnancy. However, their advantage lies in significantly reduced ability to stimulate smooth muscles. The side effects arising from the use of natural prostaglandins, such as, for example, vomiting and diarrhea, are completely or almost completely absent in this case.
    The luteolytic activity of compounds (I) was checked, for example, on homas in accordance with the procedure of Nature (A.B. Labhitwar) 1971, 230-528.
    The activity in luteolysis of hamsters 1 6-fluoro-1.6,1 of 7-non-saturated compounds, for example methyl ester 5Z, 13E, 16Z-9of, 1 Wr -15K-trioxy-16-fluoro-18,19, was compared, 20-trinor-17-phenylprost-5,13,16-trienoic acid, with activity close to erythro- and threo-16-fluoro-16,1 7-hops (enamels - methyl esters 5Z, 13E-9o , 110 -15K-trioxy-1 b8-fluoro-18,19,20-trinor-17-fench1prost-5, 13-dienr acid and 5Z, 13E-9oi: 1 W-1ЧР-trioxy-1bK-fluoro 18,19,20-trinor-17-phenylprost-5, 13-diene acid.
    The same compounds were compared in relation to the ileum of guinea pigs for contractile activity, according to the following method: ileum segments obtained from male guinea pigs were placed under a load of 0.5 g in a thermostatted Yu: 10 ml bath, which was kept at 35 ° C. In this bath, a Tyfode solution was contained in a gas mixture consisting of O 2 and CO, the tissue was held for 30 minutes 15 to ensure its stabilization before using the compounds to be tested, the reaction was recorded isotonic The sensor compared the test results of compounds presented in the form of graphs in the coordinates of the logarithm of the dose — the reaction.
    The test results, expressed in terms of the effectiveness ratio 25 as applied, are listed in Table 1, in which the compound (A) is a compound of formula (I) and the compounds (B) and (C) are comparable compounds.
    From the presented data it is clear that as a result of the use of compounds. nn (of formula I) a significant increase in luteolitic activity and a decrease in stimulatory activity on ileum with respect to the standard one is achieved, which indicates a low probability of undesirable gastrointestinal side effects,
    In tab. 2, the compound is compared to compounds (A) and (D). The compounds of formula (I) are more active and less toxic than the known compound. Compound (D) is 5Z, 13E, 45 16Z-9of, 11 °; -15K-trioxy-16-fluoro-18,19, 20-trinor-17-phenylprosta-5,13,16-trienoic acid, ,
    The luteolytic activity was defined as follows,
    Unfertilized hamsters females (Charles River, Italy), weighing 90; 120 g each night mated 1: 0 adult males. The next morning for
    50
    Vaginal swabs were checked for sperm and the first day of gestation was recorded on fertilized females. On the morning of the 5th day of pregnancy, animals subcutaneously injected
    Whether different prostaglandin derivatives (solutions in propylene glycol) were 0.1 ml / 100 g. At the 10th pregnancy after opening the abdominal cavity, under light anesthesia, the contents of the uterus were checked with ether. If it did not contain a viable fetus, the pregnancy was considered aborted. Different doses of each compound were used to determine the dose terminating the pregnancy in 50% of the animal (median effective dose).
    The acute toxicity of these compounds was determined in male mice (C-1). Each compound dissolved in propylene glycol was administered intraperitoneally at 0.05 ml / 10 g body weight per dose in 8–12 animals per dose, and the dose causing the death of 50% of the animals (median lethal dose) was determined over 7 days after drug administration.
    The compounds of formula (I) have been found to have a more prolonged therapeutic activity compared to natural prostaglandins when administered by conventional means, especially when administered orally. Prostanoids of formula (I) are more potent in their biological effects and have a narrower spectrum of biological effects compared to known prostaglandins, show greater specificity in their activity and cause significantly less undesirable side effects.
    权利要求:
    Claims (1)
    [1]
    Invention Formula
    Method for preparing 16-fluoro-16,17-α-dehydroprostanoids of general formula (I)
    THEY
    where R g is OH group or OR group, where R is lower C -C4-alkyl)
    one of R nRj-H, and the other - OHJ OD1F of RJ and R; -H and another OH, characterized in that the compound of the general formula (II)
    R
    RJ nl plH
    "4 RS Rg
    de one of R and R is H, and the other is (free or protected hydroxyl, one of R | and R is H, and the other is free or protected hydroxyl,
    fB); L
    HE
    (zrigro)
    (erythro)
    ten
    (Ttpeo)
    (treo)
    interact with a Wittig reagent containing the group: (CHj) -COR, where R has the indicated values, followed by removal of the protective groups present and the release of the target products and, if desired, convert the resulting compound of the formula fl) A compound of the formula (I) in which R is the group OR, where R is as indicated above, by a reaction of complex esterification followed by the removal of the indicated protecting groups.
    Table T
    24
    0.5
    0.96
    0.2
    table 2
    类似技术:
    公开号 | 公开日 | 专利标题
    CA1079725A|1980-06-17|Prostaglandin-acetylene analogues and process for their manufacture
    US4284646A|1981-08-18|Prostanoic acid derivatives and their preparation
    US4087604A|1978-05-02|Substituted ω-pentanorprostaglandins
    SU921465A3|1982-04-15|Method of producing prostane derivatives of salts thereof
    SE424636B|1982-08-02|ANALOGY PROCEDURE FOR PREPARATION OF 16-PHENOXY- AND 16- | -SUBSTITUTED PHENOXIPROSTA-4,5,13-TRIENE ACID DERIVATIVES
    HU182725B|1984-03-28|Process for producing dihydric-prostacyclin-derivatives
    DE2704933A1|1977-08-18|PROSTAGLANDIN ANALOGS WITH TRIPLE BONDING BETWEEN C-13 AND C-14 AND THE METHOD OF MANUFACTURING IT
    JPH068280B2|1994-02-02|9-halogen-Δ2-prostane derivative and process for producing the same
    SU1442070A3|1988-11-30|Method of producing 16-fluorine-15,17-didihydroprostanoids of general formula i
    US4004020A|1977-01-18|Novel prostanoic acid derivatives and process for the preparation thereof
    DK145083B|1982-08-23|PROSTAGLANDIN ANALOGUE FOR USE IN AGENTS FOR REGULATING THE REPRODUCTIVE CYCLOS OF HEALTHY MAMMALS
    DE2726857A1|1977-12-29|9 ALPHA, 11 ALPHA-EPOXYMETHANO- OR 11 ALPHA, 9 ALPHA-EPOXYMETHANO-9, 11.15-TRIDEOXY-PROSTAGLANDIN F-ANALOGA
    US4346228A|1982-08-24|Novel 11-oxoprostaglandin derivatives
    DK152750B|1988-05-09|ANALOGY PROCEDURE FOR THE PREPARATION OF CARBACYCLINE DERIVATIVES
    DE2729960A1|1979-01-18|NEW ACETYLENE PROSTAGLANDINE AND METHOD FOR MAKING IT
    HU181424B|1983-07-28|Process for preparing omega-nor-aromatic-13,14-dehydro-prostaglandins
    DE2610718A1|1976-10-14|NEW 16-PHENOXY-PROSTAGLANDIN COMPOUNDS
    US4070482A|1978-01-24|Prostaglandin antagonists
    US4105854A|1978-08-08|Prostanoic acid derivatives
    US4084063A|1978-04-11|8β,12α-PGF2α Compounds
    US3505387A|1970-04-07|Esters and process
    IE43689B1|1981-05-06|2-|-cyclopentane-1-heptanoic acids,methods for preparation thereof and their use
    DE2716075A1|1978-02-23|NEW INTERMEDIATE PRODUCTS AND PROCESSES FOR MANUFACTURING THROMBOXAN ANALOGA
    US4070537A|1978-01-24|17-Oxo-17-phenyl-prostaglandins
    US4039654A|1977-08-02|Prostanoic acid derivatives
    同族专利:
    公开号 | 公开日
    NO843355L|1985-03-08|
    NZ209294A|1988-03-30|
    PT79113A|1984-09-01|
    IT1180210B|1987-09-23|
    CS259869B2|1988-11-15|
    DK406484D0|1984-08-24|
    FI843285A0|1984-08-20|
    ES8607022A1|1986-05-16|
    ES8604135A1|1986-01-16|
    NL8402666A|1985-04-01|
    ZA846580B|1985-05-29|
    JPS6072859A|1985-04-24|
    IT8422159D0|1984-08-01|
    SE8404334L|1985-03-08|
    US4626597A|1986-12-02|
    ES543776A0|1986-01-16|
    HU192430B|1987-06-29|
    GB8421124D0|1984-09-26|
    FR2551436B1|1987-02-27|
    FR2551436A1|1985-03-08|
    CH662114A5|1987-09-15|
    IL72749D0|1984-11-30|
    PT79113B|1986-11-14|
    FI843285A|1985-03-08|
    GR80204B|1985-01-02|
    SE8404334D0|1984-08-30|
    DE3430626A1|1985-04-04|
    GB2146325B|1987-04-01|
    CS636084A2|1988-04-15|
    ES535551A0|1986-05-16|
    IL72749A|1988-05-31|
    HUT35638A|1985-07-29|
    GB2146325A|1985-04-17|
    BE900414A|1985-02-25|
    KR850002830A|1985-05-20|
    AU562725B2|1987-06-18|
    GB8324004D0|1983-10-12|
    DK406484A|1985-03-08|
    AU3223184A|1985-03-14|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3987087A|1971-07-29|1976-10-19|The Upjohn Company|Phenyl-substituted prostaglandin-f type analogs|
    GB1396207A|1972-04-27|1975-06-04|Upjohn Co|Prostaglandin intermediates and the preparation thereof|
    ZA744580B|1973-07-20|1975-07-30|Upjohn Co|Prostaglandin analogs|
    US4059576A|1973-08-06|1977-11-22|Hoffmann-La Roche, Inc.|11-Substituted prostaglandins|
    GB1484591A|1974-04-11|1977-09-01|Ono Pharmaceutical Co|Prostaglandin compositions|
    AU501803B2|1975-03-21|1979-06-28|Farmitalia Carlo Erba S.P.A.|Fluoro-prostaglandins|
    US4283417A|1976-06-14|1981-08-11|Pfizer Inc.|Bronchodialation with 13,14-dihydro-15-alkenyl prostaglandins|
    US4268522A|1976-06-14|1981-05-19|Pfizer Inc.|13,14-Dihydro-15-alkenyl- and 13,14-dihydro-15-alkynyl prostaglandins and analogs thereof|GB8625326D0|1986-10-22|1986-11-26|Glaxo Group Ltd|Medicaments|
    EP0310305B1|1987-10-02|1992-07-22|Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo|Cathartics|
    US5317032A|1987-10-02|1994-05-31|Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo|Prostaglandin cathartic|
    AU616564B2|1988-09-29|1991-10-31|Sumitomo Chemical Company, Limited|Novel pyrazole compounds, method for production thereof, use thereof and intermediates for production thereof|
    US5099644A|1990-04-04|1992-03-31|General Electric Company|Lean staged combustion assembly|
    JP4248022B2|1996-11-12|2009-04-02|アルコンラボラトリーズ，インコーポレイテッド|15-Fluoroprostaglandin as an intraocular pressure-lowering agent|
    US6680339B2|1996-11-12|2004-01-20|Alcon Manufacturing, Ltd.|15-fluoro prostaglandins as ocular hypotensives|
    JP2005519115A|2002-03-01|2005-06-30|アラーガン、インコーポレイテッド|Prostamide production|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB838324004A|GB8324004D0|1983-09-07|1983-09-07|16-fluoro-16 17-didehydro prostanoids|
    [返回顶部]